Company Performance Metrics
Ľuboš Marek: Chief Executive Officer- Jaromír Pastorek: Chief Scientific Officer
Mabpro Therapeutics is an early-stage biotech company building an immunotherapy platform and companion diagnostics for aggressive, hypoxic tumors.
Mabpro is the spinoff company of the Biomedical Research Centre of the Slovak Academy of Science located in Slovakia, which originally discovered and characterized Carbonic Anhydrase IX (CA IX) as the
therapeutic target and mechanism of action.
Groundbreaking research on hypoxia has been a part of the subject for which the 2019 Nobel Prize for Medicine has been awarded. Three of our team members have co-authored recent studies on hypoxia and CA IX with one of its laureates, Sir. Peter J. Ratcliffe.
Mabpro developed two core therapeutic assets – two humanized monoclonal antibodies targeting different cancer use-cases, completed most of the pre-clinical work and is preparing to launch Phase Ib/II clinical trials, holds comprehensive IP package related to CA IX-based therapies, including own proprietary IP and an exclusive license for the entire core background IP related to therapeutic applications of CA IX (owned by the Slovak Academy of Sciences).
